Table 1 Demographic and clinical characteristics of the participants at baseline.

From: Anti-obesity effect of irreversible MAO-B inhibitors in patients with Parkinson’s disease

Characteristic

iMAO-Bi group, (N = 23)

Control group, (N = 14)

P

Age (year)

65.87 ± 7.54a

61.36 ± 8.42a

0.100b

Male sex, no. (%)

12 (52.2)

10 (71.4)

0.247c

Bodyweight (kg)

67.78 ± 10.05

64.46 ± 13.28

0.395

Height (m)

1.65 ± 0.07

1.68 ± 0.09

0.356

BMI (kg/m2)

24.73 ± 2.87

22.79 ± 3.87

0.090

Anti-PD drugs administration, no. (%)

iMAO-Bi

Selegiline

20 (87.0)

0

<0.001

Rasagiline

4 (17.4)

0

0.061

Other medications

Levodopa

23 (100)

14 (100)

1.000

Carbidopa

4 (17.4)

2 (14.3)

0.760

Ropinirole

0

1 (7.2)

0.194

Entacapone

10 (43.5)

6 (42.9)

0.970

Pramipexole

8 (34.8)

6 (42.9)

0.623

Olanzapine

2 (8.7)

1 (7.2)

0.867

Median follow-up time (range, months)

6 (2–15)

11 (4.75–14.5)

 
  1. aPlus-minus values are means ± SD. Values are means ± SDs unless otherwise indicated.
  2. bDifferences in continuous variables are tested by the two independent sample t-test.
  3. cDifferences in nominal variables are tested by the chi-square test.
Back to article page